- Home
- BWAY vs CATX Comparison
BWAY vs CATX Comparison
Compare BWAY & CATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BWAY
- CATX
- Stock Information
- Founded
- BWAY 2003
- CATX 1983
- Country
- BWAY Israel
- CATX United States
- Employees
- BWAY N/A
- CATX N/A
- Industry
- BWAY Medical/Dental Instruments
- CATX Medical/Dental Instruments
- Sector
- BWAY Health Care
- CATX Health Care
- Exchange
- BWAY Nasdaq
- CATX Nasdaq
- Market Cap
- BWAY 280.7M
- CATX 239.0M
- IPO Year
- BWAY 2019
- CATX N/A
- Fundamental
- Price
- BWAY $15.77
- CATX $3.49
- Analyst Decision
- BWAY Strong Buy
- CATX Strong Buy
- Analyst Count
- BWAY 2
- CATX 11
- Target Price
- BWAY $18.00
- CATX $12.90
- AVG Volume (30 Days)
- BWAY 78.9K
- CATX 629.8K
- Earning Date
- BWAY 11-11-2025
- CATX 11-11-2025
- Dividend Yield
- BWAY N/A
- CATX N/A
- EPS Growth
- BWAY 515.14
- CATX N/A
- EPS
- BWAY 0.11
- CATX N/A
- Revenue
- BWAY $46,084,000.00
- CATX $1,235,000.00
- Revenue This Year
- BWAY $339.49
- CATX N/A
- Revenue Next Year
- BWAY $21.74
- CATX N/A
- P/E Ratio
- BWAY $55.73
- CATX N/A
- Revenue Growth
- BWAY 26.50
- CATX N/A
- 52 Week Low
- BWAY $7.70
- CATX $1.60
- 52 Week High
- BWAY $16.25
- CATX $16.19
- Technical
- Relative Strength Index (RSI)
- BWAY 67.06
- CATX 48.51
- Support Level
- BWAY $15.32
- CATX $3.33
- Resistance Level
- BWAY $16.25
- CATX $3.85
- Average True Range (ATR)
- BWAY 0.59
- CATX 0.21
- MACD
- BWAY -0.07
- CATX 0.00
- Stochastic Oscillator
- BWAY 70.25
- CATX 43.85
About BWAY BrainsWay Ltd.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.